ValuentumAd

Official PayPal Seal
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
May 22, 2014
Reynolds American and Lorillard Looking to Join Forces; Altria Benefits from SABMiller Strength
The tobacco industry is looking to consolidate, while Altria gets added boost from SABMiller.
May 12, 2014
Dividend Increases for the Week Ending May 9
Let's take a look at dividend increases for the week ending May 9.
May 11, 2014
Meet Members of the Valuentum Team at the World MoneyShow in Las Vegas - Register Free
Valuentum has been invited to present at the World MoneyShow at Caesers Palace in Las Vegas on May 13-14, 2014. Register Free.
May 6, 2014
The Alstom Situation
Let’s take a look at the situation that has GE and Siemens all worked up.
May 3, 2014
Teva Pharma: Underpriced and Misunderstood
The generics pharma giant remains one of our top ideas.
Apr 30, 2014
Earnings from 3 Internet Giants: eBay, Facebook, and Twitter
Assessing the contribution of equity value from each distinct period of Valuentum’s three-stage discounted cash flow model is a good way to assess underlying intrinsic-value uncertainty.
Apr 29, 2014
Earnings from 8 Interesting Ideas
Let’s examine the recent earnings reports from 8 firms that you should know about.
Apr 25, 2014
Earnings from 15 Dividend Growth Giants
Let’s take a look at recent results from a number of big dividend payers.
Apr 23, 2014
Perhaps Nothing Stronger Than Aerospace
Boeing put up strong first-quarter results and showcased its massive backlog of unfulfilled orders.
Apr 22, 2014
Big News in Big Pharma
Pfizer is looking to scoop up AstraZeneca, Valeant and Ackman eye Allergan, Eli Lilly and Novartis strike a deal in animal health, and Novartis picks up GSK’s oncology portfolio.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.